Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Carlsmed, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Carlsmed, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:10 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001794546-26-000016
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Cost of sales | 4,398 | 3,214 | 8,089 | 5,767 |
| Gross profit | 14,542 | 8,869 | 26,967 | 16,505 |
| Operating expenses: | ||||
| Research and development | 6,040 | 4,160 | 11,218 | 7,310 |
| Sales and marketing | 11,920 | 7,869 | 22,217 | 14,608 |
| General and administrative | 7,618 | 3,342 | 13,844 | 6,808 |
| Total operating expenses | 25,578 | 15,371 | 47,279 | 28,726 |
| Loss from operations | (11,036) | (6,502) | (20,312) | (12,221) |
Item 1. Financial Statements.
FAQ
- What is Carlsmed, Inc.'s R&D?
- Carlsmed, Inc. (CARL) reported R&D of $6.04M in Q2 2026.
- How has Carlsmed, Inc.'s R&D changed year-over-year?
- Carlsmed, Inc.'s R&D increased by 45.2% year-over-year, from $4.16M to $6.04M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Carlsmed, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude